Uncategorized

Kelyniam Global, a maker of custom cranial implants, announced results for its year ended December 31, 2022.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023.

CANbridge Pharmaceuticals, Inc. announced that long-term follow up data from the Phase 1/2 study of CAN008 plus temozolomide/radiotherapy in newly diagnosed glioblastoma multiforme showed a long-term survival rate of 67% at five years, three years after the trial ended.

The guidance fills in details for one of the central pharmaceutical provisions of the Inflation Reduction Act, signaling how the agency will use its new authority.

Although the AI scribe understood most verbal commands and handled most medical documentation, it was at times unable to form a medical plan.

The Affera system gives physicians a choice between pulsed field ablation and radiofrequency to treat atrial fibrillation.

Douglas Devine will stay on as a consultant through 2024, as the company goes through a restructuring to become “a larger digital healthcare organization.” 

Some states are proposing to unwind Medicaid coverage more slowly, while others are moving more quickly to focus on reducing budgetary costs, according to a survey from the Kaiser Family Foundation.

If Tandem can prove to regulators that the system can help manage young children’s diabetes, it could compete with Medtronic and Insulet, which have devices that are indicated for use in kids as young as two years.

Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.